Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy - SC-3G2A
Latest Information Update: 08 Oct 2025
At a glance
- Drugs Phleum pratense cluster allergy immunotherapy ROXALL Medizin GmbH (Primary)
- Indications Allergic rhinitis; Asthma; Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Roxall Medizin GmbH
Most Recent Events
- 08 Oct 2025 New trial record